NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
RINVOQ (upadacitinib) by AbbVie is janus kinase inhibitors [moa]. Approved for rheumatoid arthritis, atopic dermatitis, ulcerative colitis and 3 more indications. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RINVOQ (upadacitinib) is an oral Janus Kinase (JAK) inhibitor approved by the FDA on August 16, 2019, available as an extended-release tablet. It works by selectively inhibiting JAK enzymes, which are critical mediators of inflammatory signaling pathways. While specific indications are not detailed in the provided data, upadacitinib is approved for multiple inflammatory and autoimmune conditions. The product is currently in its peak commercial lifecycle stage for a small-molecule JAK inhibitor.
$1.0BPart D
11.8 years to LOEMechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Indications (6)
Worked on RINVOQ at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.